DC
TCRT icon

Davenport & Co’s Alaunos Therapeutics TCRT Stock Holding History

Davenport & Co’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-97
Closed -$108K – 624
2016
Q1 		$108K Buy
+97
New +$99.3K ﹤0.01% 563
2015
Q4 		– Sell
-83
Closed -$112K – 610
2015
Q3 		$112K Sell
83
-12
-13% -$19.8K ﹤0.01% 560
2015
Q2 		$170K Buy
+95
New +$147K ﹤0.01% 557

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Davenport & Co's TCRT Position: Q2 2016 in Review

Davenport & Co sold out of Alaunos Therapeutics (TCRT) in Q2 2016, closing a stake of 97 shares — an estimated $108K sold.

Davenport & Co first reported a position in TCRT in Q2 2015 and held it in 3 quarters. The position peaked at $170K in Q2 2015. 154 funds tracked by Wall St. Rank hold TCRT as of Q2 2016.

  • Davenport & Co reported no remaining Alaunos Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Davenport & Co sold 97 Alaunos Therapeutics shares in Q2 2016, an estimated $108K.
  • Davenport & Co first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 3 quarters.
  • Davenport & Co's Alaunos Therapeutics position peaked at $170K in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2016.

Based on Davenport & Co's 13F filing for Q2 2016, filed 12 Jul 2016.